BioCentury
ARTICLE | Clinical News

Paper suggests Aravive compound could block Zika

January 10, 2017 11:59 PM UTC

In a study published Tuesday in Cell Reports, researchers from INSERM and Aravive Biologics Inc. (Houston, Texas) said Aravive’s preclinical candidate Aravive-S6 could protect glial cells from Zika infection.

Aravive-S6 is an Fc-fusion protein that blocks activation of the growth arrest-specific 6 (GAS6)-AXL receptor tyrosine kinase (AXL; UFO) signaling pathway by serving as a decoy that prevents the binding of GAS6 to the AXL receptor...